Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163799 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01163799 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 9 participants.
The verdict
NCT01163799, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess Alefacept in combination with alemtuzumab induction and calcineurin inhibitor and corticosteroid withdrawal.
Interventions
- DRUG Alefacept (ASP0485)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163799
The ClinicalTrials.gov registry entry for NCT01163799 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alefacept (ASP0485) is the first listed.
NCT01163799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163799 about?
NCT01163799 is a clinical study titled "A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients". The purpose of this study is to assess Alefacept in combination with alemtuzumab induction and calcineurin inhibitor and corticosteroid withdrawal.
What is the current status of trial NCT01163799?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01163799?
The interventions under investigation include: Alefacept (ASP0485) (DRUG).
Who is sponsoring clinical trial NCT01163799?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.